The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known also as ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced that Basaglar (insulin glargine injection 100 units/mL) is available by prescription in the US Basaglar is a follow-on ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...

Medicare Part D may cover Basaglar, a long-acting insulin, and under the Inflation Reduction Act, the cost should not exceed $35 per month. The availability of Basaglar under Medicare Part D depends ...